EMBC
Embecta Corp. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2025-11-25
Figures on this page computed 2026-11-08 12:24 UTC
Last close
6.52USD
Market data, 2026-11-04
Except where said otherwise: 10-K for 2025, filed 2025-11-25
3.8xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001872789-25-000036
- Reported in
- USD
- computed
- 10-K for 2025, filed 2025-11-25
29.7%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001872789-25-000036
- Reported in
- USD
- 10-K for 2025, filed 2025-11-25
- 10-K for 2025, filed 2025-11-25
- 10-K for 2025, filed 2025-11-25
- 10-Q for 2025, filed 2026-08-07
- 10-K for 2025, filed 2025-11-25
- 10-Q for 2025, filed 2026-08-07
8.8%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001872789-25-000036
- Reported in
- USD
- 10-K for 2025, filed 2025-11-25
- 10-K for 2025, filed 2025-11-25
16.9%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001872789-25-000036
- Reported in
- USD
- 10-K for 2025, filed 2025-11-25
- 10-K for 2025, filed 2025-11-25
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001872789-25-000036
- Reported in
- USD
- 10-K for 2025, filed 2025-11-25
- 10-Q for 2025, filed 2026-08-07
5.2%Dividend yield
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
- computed
- computed
- computed
- computed
- Computed from the filing for 2025, filed 2025-11-25
Growth is the furthest below its sector's middle: 0.28 against 0.47 on the market's range.
Against its rival
lens 4 of 9Measure by measure
behind on 2 of 4- Profit on each unit of sales8.8%11.2%Behind
Higher is better here.
- Return on the capital it uses29.7%n/an/a
Higher is better here.
- Sales growth over five years-0.1%6.3%Behind
Higher is better here.
- Debt against equityn/an/an/a
Lower is better here.
- Gross margin62.6%42.3%Ahead
Higher is better here.
- Price against earnings3.8x20.7xAhead
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against Kamada Ltd., EMBC is behind on 2 of 4 measures.
Against Kamada Ltd., EMBC is behind on 2 of 4 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2025-11-25
Profit on each unit of sales8.8%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001872789-25-000036
- Reported in
- USD
Return on the capital it uses29.7%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001872789-25-000036
- Reported in
- USD
Sales growth over five years-0.1%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001872789-25-000036
- Reported in
- USD
Debt against equityn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001872789-25-000036
- Reported in
- USD
Gross margin62.6%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001872789-25-000036
- Reported in
- USD
Price against earnings3.8x
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001872789-25-000036
- Reported in
- USD